idebenone
Orphan DrugEMA Approved
Description
Idebenone is a synthetic analog of coenzyme Q10 with antioxidant properties. It is approved in the European Union for the treatment of visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON). The drug has also been investigated for other mitochondrial and neurodegenerative conditions including certain forms of muscular dystrophy.
Indications & Therapeutic Use
Leber hereditary optic neuropathy, investigational: Duchenne muscular dystrophy, Friedreich ataxia
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
idebenone
| Generic Name | idebenone |
| Brands | 1 brand available |
| Active Ingredient | idebenone |
| Drug Class | Leber hereditary optic neuropathy |
| Manufacturer | Santhera Pharmaceuticals |
| Dosage Forms | oral tablet, 150 mg |
| Medical Code | N06BX13 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 21 days |
| Reg. Status | EMA Approved |
| Clinical Trial | NCT02774005 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes